Filing Flows › Interpace Biosciences (IDXG) › Q3 2025
Interpace Biosciences (IDXG) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Interpace Biosciences (IDXG) reported revenue of $8.8M for the third quarter 2025 (Q3 2025), -29% from a year earlier and -5% from the quarter before. Operating margin was 13.1%, net earnings $911K (10.4% of revenue).
Interpace Biosciences, Q3 2025: revenue $8.8M (-29% year over year), operating margin 13.1%, net earnings $911K, operating cash flow $1.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.8M | -5% | -29% |
| Gross profit | $5.4M | +3% | -31% |
| Operating profit | $1.1M | — | -50% |
| Net earnings | $911K | — | -46% |
| Operating cash flow | $1.9M | +273% | -8% |
| Free cash flow | $1.8M | — | +14% |
What changed
Revenue was $8.8M in Q3 2025, down 29% year over year and down 5% from the previous quarter.
Gross margin was 62.1%, down 2.2 points from a year earlier. Operating profit was $1.1M, a 13.1% margin (down 5.6 points year over year). Operating expenses fell 23% while revenue fell 29%. Net earnings were $911K, down 46% year over year. The effective tax rate was -1.2%.
Operating cash flow was $1.9M (down 8% year over year), 213% of net earnings. Non-cash charges added back $111K of depreciation and amortization and $7K of share-based compensation. Working capital and other items added $909K. Capital expenditures of $117K left free cash flow of $1.8M.
Questions
What was Interpace Biosciences' revenue in the third quarter 2025?
Interpace Biosciences (IDXG) reported revenue of $8.8M for the third quarter 2025 (Q3 2025), -29% from a year earlier and -5% from the quarter before.
Was Interpace Biosciences profitable in the third quarter 2025?
Operating profit was $1.1M (13.1% of revenue) and net earnings $911K.